By Eisai Inc.

E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1

TOKYO , Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") announced today that the results from a Phase Ib clinical trial ( NCT06462404 ) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10 .

These data demonstrate that once-daily dosing of E2086 has the potential to improve daytime wakefulness in individuals with narcolepsy type 1 (NT1).

Clinical Trial Design

This randomized, double-blind, single-dose, multiple crossover, Phase Ib clinical trial was conducted in the United States and Canada to evaluate th

See Full Page